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Abstract
Collagen synthesis is severely diminished in osteoarthritis; thus, enhancing it may help the regeneration of cartilage. This 
requires large amounts of glycine, proline and lysine. Previous works of our group have shown that glycine is an essential 
amino acid, which must be present in the diet in large amounts to satisfy the demands for collagen synthesis. Other authors 
have shown that proline is conditionally essential. In this work we studied the effect of these amino acids on type II collagen 
synthesis. Bovine articular chondrocytes were cultured under a wide range of different concentrations of glycine, proline and 
lysine. Chondrocytes were characterized by type II collagen immunocytochemistry of confluence monolayer cultures. Cell 
growth and viability were assayed by trypan blue dye exclusion method. Type II collagen was measured in the monolayer, 
every 48 h for 15 days by ELISA. Increase in concentrations of proline and lysine in the culture medium enhances the syn-
thesis of type II collagen at low concentrations, but these effects decay before 1.0 mM. Increase of glycine as of 1.0 mM 
exceeds these effects and this increase continues more persistently by 60–75%. Since the large effects produced by proline 
and lysine are within the physiological range, while the effect of glycine corresponds to a much higher range, these results 
demonstrated a severe glycine deficiency for collagen synthesis. Thus, increasing glycine in the diet may well be a strategy 
for helping cartilage regeneration by enhancing collagen synthesis, which could contribute to the treatment and prevention 
of osteoarthritis.
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Introduction
Osteoarthritis is a degenerative joint disease characterized 
by tensile stiffness, degeneration and progressive loss of 
articular cartilage. It is one of the most frequent causes of 
pain, loss of function and disability in adults affecting to up 
40% of those aged over 65 (Arden and Nevitt 2006; Bijlsma 
et al. 2011; Dawson et al. 2004; Mannoni et al. 2003; Zhang 
et al. 2007). Radiographic evidence of osteoarthritis occurs 
in the majority of people by 65 years of age and in about 
80% of those aged over 75 years (Arden and Nevitt 2006).
Degeneration of the cartilage in osteoarthritis mainly 
affects the collagen content in the matrix structure (Bank 
et al. 1997; Dahlberg et al. 2000; Wu et al. 2002). On the 
other hand, there is also an increase in the synthesis of 
matrix molecules, including type II collagen (Lohmander 
et al. 2003; Nelson et al. 1998) and proteoglycans (Rizkalla 
et al. 1992) in an attempt to preserve the matrix. Degen-
eration of the matrix affects the mechanical stability of the 
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tissue as well as causes disturbance of chondrocyte func-
tion and survival because of the vital chondrocyte–matrix 
interactions (Buckwalter et al. 2005; Horton et al. 1998; 
Monfort et al. 2006). In osteoarthritis collagen synthesis is 
substantially greater than in non-osteoarthritic tissues, but 
it is not sufficient to compensate for the excessive degrada-
tion (Dodge and Poole 1989; Heinegård and Saxne 2011; 
Lippiello et al. 1997; Nelson et al. 1998; Price et al. 1999; 
Rizkalla et al. 1992). The progressive imbalance between 
matrix degradation and its regeneration leads to a marked 
decrease in the type II collagen content, which eventually 
results in cartilage damage (Aigner and Stove 2003; Hol-
lander et al. 1995; Nelson et al. 1998; Rizkalla et al. 1992).
The two components of the cartilage (matrix and chon-
drocytes) are mutually dependent. Chondrocytes deal with 
matrix synthesis and turnover, and the matrix structure is 
necessary for the life of chondrocytes. Therefore, degen-
eration of the cells and the matrix in osteoarthritis is auto-
catalytic, which causes the disease to progress, like a snake 
eating its own tail. However, these events do not occur 
simultaneously. Several studies show that collagen damage 
is the primary event, while the breakdown of proteoglycans 
could be a consequence of a poor collagen support (Dodge 
and Poole 1989; Hollander et al. 1995; Kojima et al. 2001; 
Poole et al. 2002; Price et al. 1999; Rizkalla et al. 1992; Wu 
et al. 2002).
Today, there is no cure for this common disease, which 
for epidemiologists is an enigmatic condition (Arden and 
Nevitt 2006; Buckwalter and Mankin 1998; Buckwalter et al. 
2005; Felson and Nevitt 2004; Heinegård and Saxne 2011). 
Only symptomatic treatment for pain relief is possible, 
including pharmacological, non-pharmacological, and sur-
gical approaches (Bijlsma et al. 2011). As Schnitzer (1993) 
has remarked, the treatment of osteoarthritis has been based 
entirely on empirical, largely uncontrolled observations, and 
the focus of therapy has been to relieve pain, the primary 
symptom of the disease, in hopes of increasing function, 
such as ability to walk. We think that this sentence summa-
rizes the two main aspects that must be resolved: the lack 
of a theoretical-formal background, and the need to find a 
real solution beyond relieving the prejudicial and annoying 
symptoms.
The regeneration of the cartilage is the main target to 
solve the problem, and its main key could be the regenera-
tion of collagen (Nelson et al. 1998; Aigner and Stove 2003).
Glycine, proline and lysine play a special role in colla-
gen structure (Bowes and Kenten 1948; Pauling and Corey 
1951), and their insufficient availability could be a cause 
to make collagen synthesis and regeneration difficult. Gly-
cine, which is 33% of collagen residues, has been typically 
classified as a ‘non-essential’ amino acid because human 
metabolism can synthesize it from serine. However, in pre-
vious work (Meléndez-Hevia and de Paz-Lugo 2008) we 
have shown that the glycine synthesis pathway has a strong 
stoichiometric restriction that limits its production, indepen-
dently of the capacity and the regulatory mechanisms of the 
enzymes, as shown in Fig. 1.
The biosynthesis of glycine from serine occurs in a reac-
tion that does not establish a bifurcation metabolite from 
a common intermediate towards two alternative products 
whose fluxes can be distributed independently; rather it is 
an enzyme-branching break with fixed stoichiometry yield-
ing two different products: glycine, and the  [C1] unit car-
ried by tetrahydrofolate. This determines that the production 
of either of them is conditioned by the consumption of the 
other because both have to be consumed in equal quantity. 
This constraint between the two independent pathway series 
can cause a lack of one of them because the product that is 
less used will determine a mathematical limit on the produc-
tion of the second. No previous case of such a stoichiometric 
constraint that can lead to a deficiency of any product has 
been described in the metabolic network. We have called it 
(and other similar cases that may eventually be discovered 
in the future) weak links in metabolism (Meléndez-Hevia 
and de Paz-Lugo 2008).
On the other hand, the synthesis of collagen microfibril 
is a very complex process where a high fraction (30–90%, 
depending on the tissues and the age of individuals) of the 
newly synthesized collagen is degraded in the procollagen 
cycle within minutes of its synthesis to achieve the correct 
triple helix folding (see Meléndez-Hevia et al. 2009 and ref-
erences therein). This greatly increases the need for glycine 
since most of it, which comes from procollagen degrada-
tion in the cycle, is not available for reuse (Gibson et al. 
2002). Hydroxyproline and hydroxylysine cannot be recy-
cled because they must be incorporated in the procollagen 
peptide as proline and lysine, respectively, thereby greatly 
increasing the needs for these amino acids as well.
Our results reported in a subsequent work (Meléndez-
Hevia et al. 2009) showed that the use of the  [C1] unit is 
much lower than the need for glycine, especially for colla-
gen synthesis. Thus, glycine must be considered an essential 
amino acid because the capacity of its synthesis is much 
lower than its actual need. We also showed that this defi-
ciency is not covered with a regular diet so glycine should 
be added to it as a nutritional supplement in high amounts, 
about 10 g/day. A review of the data on this subject cor-
roborates the need for glycine in the diet (Wang et al. 2013). 
Wu et al. (2011) have shown that proline it is condition-
ally essential under some conditions, which means that the 
capacity of its synthesis could not sufficiently account for 
its need. Finally, lysine is an essential amino acid, whose 
availability depends entirely on the diet.
Proteoglycans have no special abundant amino acid such 
as glycine or proline in collagen; see, e.g., Uldbjerg et al. 
(1983). Moreover, glucosamine and any sugar derivatives, 
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such as galactosamine, main components and precursor of 
proteoglycans do not have a problem of design in its synthe-
sis pathway like glycine has. Mankin et al. (1981) demon-
strated that the use of glucosamine was the same in normal 
and osteoarthritic samples. Results reported by Qu et al. 
(2006) showed that glucosamine and other similar sugars 
have no effect on the synthesis of proteoglycans by chondro-
cytes in vitro. Roman-Blas et al. (2017) confirmed the inef-
fectiveness of glucosamine and chondroitin sulfate showing 
that the placebo had even better effect that these products.
Thus inefficient collagen synthesis by chondrocytes to 
renew the old degraded molecules may be a main cause of 
osteoarthritis, in agreement with Aigner and Stove (2003). 
Rizkalla et al. (1992) pointed out that “if collagen damage 
could be prevented and its repair promoted then it may be 
possible for cartilage to repair itself”.
Therefore, according to the reasoning presented above, 
we can assume that a cause of osteoarthritis could be a poor 
availability of some essential amino acids to build collagen. 
Thus, collagen synthesis could be improved if chondrocyte 
metabolism had the amino acids mentioned (especially 
glycine) available in the necessary quantities. In this work, 
we have studied the effect of glycine, proline and lysine on 
the synthesis of type II collagen in articular chondrocytes 




Hyaluronidase type V, pancreatic elastase, collagenase type 
IV (Clostridium histolyticum), penicillin-G, Sigma-Aldrich 
Ham’s F12 medium (Sigma-Aldrich 2017), fetal bovine 
serum (FBS), bovine serum albumin (BSA), Tris, Hepes, 
trypan blue, and Giemsa stain solution were obtained from 
Sigma (USA); pepsin, pronase (Streptomyces griseus) and 
streptomycin sulfate were obtained by Fluka (USA); trypsin 
was obtained from Gibco (USA); mouse monoclonal pri-
mary antibody directed against bovine type II collagen was 
obtained from Labvision Corporation (USA); FITC conju-
gated secondary antibody (sheep anti mouse IgG conjugated 
to fluorescein isothiocyanate) was obtained from Stressgen 
Biotechnologies Corporation (USA); Glycine, l-proline, 
l-lysine, l-isoleucine and l-aspartic acid were Pharma grade, 
Fig. 1  Glycine metabolism pathways. Metabolic pathways involved 
in the biosynthesis of glycine, and its use for different metabolic 
functions. a Glycolysis, involving the 3-phosphoglycerate (3PGA) 
metabolite bifurcation. b Pathway of serine and glycine synthesis 
starting from 3PGA. (b1) Reaction of glycine synthesis from serine 
by glycine hydroxymethyltransferase (EC 2.1.2.1). This is an enzyme-
branching break with fixed stoichiometry, which converts serine into 
glycine with the transfer of a  [C1] unit to tetrahydrofolate (THF) giv-
ing 5,10-methylene tetrahydrofolate (THF-[C1]). (b2) Set of reactions 
that use the  [C1] unit from THF-[C1] regenerating free THF so that it 
can participate again in reaction b1. (b3) Irreversible reaction of the 
glycine cleavage system (EC 1.4.4.2), which makes a sink of glycine. 
c Processes involved in THF-[C1] metabolism to different products 
including methyl transfers by adenosyl methionine (Ado-Met). d Pro-
cesses of protein biosynthesis involving glycine, especially the syn-
thesis of collagen. e Set of pathways that use glycine as metabolite for 
other biosynthesis processes. See Meléndez-Hevia and de Paz-Lugo 
(2008)
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obtained from Quimipur (Spain); all other chemicals were of 
reagent grade and were purchased from Sigma, Quimipur, 
and Panreac (Spain).
Culture media and reagents
Basal culture medium (BCM)—Ham’s F12 medium con-
taining 10% fetal bovine serum (FBS), 100 U/mL penicillin 
and 100 µg/mL streptomycin. Hank’s buffered salt solution 
(HBSS) (Hanks 1976)—prepared in our laboratory at pH 
7.2 containing 100 U/mL penicillin and 100 µg/mL strepto-
mycin. Phosphate-buffered saline (PBS)—Dulbecco’s phos-
phate-buffered saline at pH 7.2. Concentrated Tris buffered 
saline (TBS10)—1 M Tris, 2.0 M NaCl, 50 mM  CaCl2, pH 
7.9. Diluted Tris buffered saline (TBS1)—100 mM TRIS, 
200 mM NaCl, 5.0 mM  CaCl2, pH 8.0. Pepsin solution 
(PepS)—10 mg pepsin/mL dissolved in 0.05 M acetic acid. 
Pancreatic elastase solution (PES)—1 mg elastase/mL dis-
solved in TBS1. Trypsin solution—250 mg trypsin, 20 mg 
EDTA per 100 mL PBS, pH 7.5.
Isolation and cultures of chondrocytes
Isolation and culture of chondrocytes were performed by a 
modified protocol, according to previously described meth-
ods (Oesser and Seifert 2003; Qu et al. 2006). Cartilage sam-
ples were dissected aseptically from the metacarpophalan-
geal joints of 12- to 18-month-old steers obtained from a 
local abattoir within 2 h after slaughter. Shavings of hyaline 
cartilage (3 × 3×1 mm) were removed from the outer two-
thirds of the articular cartilage, such that contamination with 
bone cells or other connective tissue cells could be avoided. 
Cartilage slices were minced and extensively washed with 
HBSS. The cartilage was diced aseptically into ≈ 1-mm3 
pieces and subsequently digested with 2000 U/mL hyaluro-
nidase and 30 U/mL pronase in HBSS for 60 min at 37 °C. 
Then, cartilage fragments were washed twice in HBSS and 
transferred into a collagenase solution (8 U/mL) in BCM 
at 37 °C for 7 h with gentle shaking. During this 7 h, col-
lagen network was digested and cells were liberated to the 
culture medium. Fibroblasts do not resist this long treat-
ment with collagenase, so we have avoided their potential 
contamination in the cultures. The resulting cell suspension 
was filtered through a 20-µm nylon mesh and centrifuged at 
1000 rpm for 10 min. After centrifugation the supernatant 
was discarded and the pellet resuspended in 5 mL of BCM.
The vital chondrocytes extracted in the final cell suspen-
sion were counted by the trypan blue exclusion method in a 
Neubauer chamber. Cells were seeded in 24-well plates at 
a density of 150,000 cells/mL and cultured at 37 °C in the 
basal medium (BCM) under an atmosphere of 5%  O2, 5% 
 CO2 and 90%  N2 with 85% humidity. The culture medium 
was changed every 48 h for the duration of the experiments. 
No subculture cells were used to avoid loss of their differen-
tiated type II collagen phenotype (Cao et al. 1997). All oper-
ations with cells (isolation, seeding and changes of culture 
medium) were carried out in a Telstar PV-100 vertical lami-
nar flow bench. Cell cultures were carried out in a benchtop 
 CO2 8 IR incubator (New Brunswick Scientific). At 24 h 
after cells seeding, when they become attached and evenly 
distributed in the wells, glycine, l-proline, l-lysine, l-isoleu-
cine, or l-aspartic acid were added to the wells at appropriate 
concentrations according to each experiment in the range of 
0.25–7.0 mM. Cells without amino acid addition were used 
as the control group. All the cells in the experimental and 
control groups were incubated for 15 days from seeding, 
analyzing cell shape, growth, viability, and type II collagen 
every 48 h. All experiments were made from three different 
cows on different days, taking duplicate samples in each.
Cell shape, growth and viability
Chondrocyte shape in the culture monolayers was checked 
by Giemsa stain. The cells were isolated from the monolay-
ers by rinsing with PBS to remove traces of serum and incu-
bated with 250 µL of trypsin solution for 2 min at room 
temperature. After eliminating the excess of trypsin, leav-
ing a few drops over the monolayer, cells were incubated at 
37 °C for 15 min in the  CO2 incubator. Then, 1 mL of BCM 
was added to the cell layer and cells were recovered. Number 
of total cells and cell viability were assessed by trypan blue 
dye exclusion method with the Vi-CELL XR cell viability 
analyzer (Beckman Coulter, California, USA).
Immunocytochemistry of monolayer cultures
Chondrocytes were seeded on gelatinized glass coverslips at a 
density of 150,000 cells/mL and cultured as described above 
until reaching confluence. Then the cells were fixed with 2% 
(w/v) paraformaldehyde for 30 min at room temperature. After 
three washes with PBS, autofluorescence was eliminated with 
sodium borohydride 1 mg/mL for 10 min. Then, after rinsing 
in PBS, cells were permeabilized using 0.2% Triton X-100 
in PBS for 10 min and endogenous peroxidase activity was 
blocked with 3% (w/v) BSA in PBS/0.1% Triton X-100 for 
10 min. The chondrocytes were rinsed again three times in 
PBS and incubated for 1 h with mouse monoclonal primary 
antibody directed against bovine type II collagen (Labvision) 
diluted at 3% (w/v) in BSA/PBS. After washing again in PBS, 
the cells were incubated for 30 min with the FITC conjugated 
secondary antibody (Stressgen) diluted at 3% (w/v) in BSA/
PBS. The samples were finally mounted on Fluoromount-G 
fluorescent assembly (SouthernBiotech, Alabama, USA) and 
examined under a Leica DM IL inverted microscope with 
digital camera, phase contrast and fluorescence equipment. 
As negative control, the primary antibody was replaced by 
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3% (w/v) BSA in PBS. Cells/matrix proportion volume was 
estimated using the CorelDraw Graphics Suite X7 software 
(Corel Corporation, Canada).
Quantification of type II collagen
Type II collagen was assayed in the monolayer, where the 
chondrocytes are embedded in the matrix, every 48 h for 
15 days after amino acid additions. Bovine type II collagen in 
the cell monolayers was determined by means of the Arthro-
gen-CIA type II collagen capture ELISA kit (Chondrex, Inc., 
MD Biosciences, Zurich). To solubilize the newly synthesized 
collagen, the cell culture medium was removed and the cell 
layers were washed with HBSS. After removing the HBSS, 
250 µL-0.05 M acetic acid was added to each well; cells were 
dispersed with careful scraping, and the cell suspension of 
each well was transferred to a microcentrifuge tube and were 
incubated with 25 µL-pepsin solution (PepS) for 24 h at 4 °C. 
Subsequently, 25 µL TBS10 were added to stop the reac-
tion, and then 2.5 µL NaOH 6 N are added to adjust pH. The 
remaining polymeric collagen was monomerized by adding 
25 µL of pancreatic elastase solution (PES) to each tube and 
incubated for 24 h at 4 °C with gentle shaking. Then the tubes 
were centrifuged at 10,000 rpm for 5 min, and aliquots of the 
supernatant were taken for type II collagen assay by ELISA 
method with the Chondrex Type II Collagen Detection Kit, 
following the assay protocol described by the manufacturer 
(Chondrex, Inc. 2016) using a Greiner high-binding multiwell 
96 plates. Artwork (Figs. 1, 4, 5, 6) was created with Corel 
DRAW Graphics Suite X7.
Statistical analysis
All the quantitative values were obtained from three experi-
ments with three different cows, analyzing two or three 
samples in each one, by extracting the samples from each 
monolayer in the culture. All coefficients of variation 
V = (s/X) × 100 calculated for each group of the two or three 
assays of each sample (controls and each addition of amino 
acids) were between 4.5 and 5.7, which mean low standard 
error in the assay procedure. The results presented are the 
mean, with the error bars (SD) of the three different samples. 
The significance of differences between treated groups and 
non-treated control were assessed by an ANOVA test, followed 
by the Tukey test for multiple comparisons using GraphPad 
Prism 4 software (Motulsky 2003). Differences with P < 0.05 
were considered to be statistically significant.
Results
Chondrocytes cultures
Giemsa stain of cells was made to check chondrocyte mor-
phology. Figure 2 shows a typical result where chondrocytes 
have their normal polygonal shape.
In order to check the validity of the experimental model, 
we assayed in the monolayer type II collagen by specific 
immunofluorescence stain; a typical result is shown in 
Fig. 3.
The close relationship remarked above between cells 
shape and survival, and matrix structure, demonstrates a 
good development of the sample in the monolayer experi-
mental model. According to Kuettner et al. (1982), chondro-
cytes begin to resynthesize pericellular matrix after becom-
ing anchored to the plastic surface, which is fully established 
after 3–4 days in culture and is morphologically indistin-
guishable from that of the normal chondrocytes in vivo. The 
results shown in Fig. 3 agree with this statement. Trypan 
blue exclusion stain showed that supplementing the culture 
medium with any amount of amino acids used in our experi-
ments did not affect the viability of the cells. All cultures 
were between 80 and 89% viability with no significant dif-
ferences among them for each amino acid concentration, 
nor was there any significant change of viability during the 
15 days of culture after 2 days necessary for monolayer sta-
bilization, both in controls and in cultures with amino acids 
added at any concentration. Standard deviations were the 
Fig. 2  Bovine chondrocytes in the well plate monolayer (40× objec-
tive). Cells were fixed and stained after 7  days of culture with 
Giemsa. The cultured cells look normal showing their typical pyrami-
dal shape.
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same range in all cultures, all of them between 3.28 and 
8.97.
Effect of amino acids on collagen synthesis
Figure 4 shows the progress of type II collagen synthesis 
during the 15 days of tissue culture. As can be seen, in 
the basic control conditions (gly 0.25 mM, pro 0.15 mM, 
lys 0.5 mM) there is an increase in type II collagen syn-
thesis until day 13 and the synthesis decays thereafter. 
Addition of the three amino acids to the medium to reach 
1.5 mM produces an increase in the synthesis, but the pro-
file effects of proline and lysine are similar to the control, 
while the effect of glycine is greater than all of them and 
does not decay at the end of the culture. Addition of l-iso-
leucine and l-aspartic acid (used as control amino acids) 
to the medium at the same concentrations did not produce 
any significant effect on collagen production different from 
the basic control.
Fig. 3  Immunofluorescence staining of type II collagen in cultured 
chondrocytes (40× objective) in monolayer. Typical result of the 
monolayer culture with glycine enriched basal medium. Cells were 
fixed and stained after 7  days of culture with specific antibodies 
against type II collagen. The picture demonstrates that cultured cells 
are indeed chondrocytes because, apart from their typical shape, they 
synthesize type II collagen. The picture shows only the dyed type II 
collagen, and the cells contours are seen by contrast. Similar results 
were obtained after treatment with other amino acids in the culture 
medium
Fig. 4  Progress in collagen synthesis by articular chondrocytes. Spe-
cific effect of each amino acid 1.5 mM on type II collagen production 
by chondrocytes in the monolayer during culture development. Green 
hexagon: glycine (green line); blue square: l-proline (blue line); red 
rectangle: l-lysine (red line); dark blue circle: l-aspartic acid (dark 
blue line); purple circle: l-isoleucine (purple line); gray circle: con-
trol (C) (black line)
Fig. 5  Effect of each amino acid concentrations on type II collagen 
synthesis. Type II collagen production by chondrocytes in the mon-
olayer at 13 days (a) and 15 days (b) of culture development under 
each amino acid concentration: green hexagon: glycine (green line); 
blue square: l-proline (blue line); red rectangle: l-lysine (red line); 
dark blue circle: l-aspartic acid (dark blue line); purple circle: l-iso-
leucine (purple line). The dotted line (C) means the collagen produc-
tion under control conditions in the regular medium (gly 0.25 mM, 
pro 0.15 mM, lys 0.5 mM). The area marked in gray to the left of the 
graph shows the normal range of concentrations of these amino acids 
in the plasma (Felig and Wahrent 1971; Goodwin 1968; Javitt et al. 
2001; Nakazawa et al. 1982; Summer and Roszel 1965)
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The increase of type II collagen in the monolayer was 
different according to each amino acid concentration in 
the medium. Figure 5 shows the results at 13 and 15 days 
of culture.
Results in Fig. 5b, at 15 days culture, show that the 
need of glycine is the highest, having to be 1.5 mM to 
reach about 225% collagen increase over the control. The 
same effects were achieved with proline and lysine, but 
their need was lower, up to 0.6 and 0.8 mM, respectively. 
However, the most important feature of these results is that 
glycine maintains its stimulating effect at higher concen-
trations (up to 7 mM), while the increased concentrations 
of proline and lysine declined their effects, their being at 
1.5 mM one half and one-third, respectively, of the effect 
achieved by glycine. Increased concentrations of l-aspartic 
acid or l-isoleucine in the medium up to 7.0 mM did not 
produce any effect, which demonstrates the specific need 
for glycine, proline and lysine.
Effect of amino acids on cell growth
Increased concentrations of glycine, proline or lysine in 
the assayed ranges that promote increase in collagen syn-
thesis did not make changes in cell growth. This effect was 
seen for all concentrations of amino acids assayed. Fig-
ure 6 shows the results at concentration of each amino acid 
that promotes the highest collagen synthesis (7.0 mM gly-
cine, 0.6 mM l-proline, 0.8 mM l-lysine); l-aspartic acid 
and l-isoleucine (not shown) did not affect cell growth 
significantly.
Discussion
Results presented in Figs. 4 and 5 show that increased 
concentrations of glycine, proline and lysine in the basal 
medium enhance type II collagen synthesis. The effects of 
these amino acids are independent as they are independ-
ent variables because the degradation of any one of them 
does not give rise to a specific metabolite for the synthe-
sis of any other. These results suggest that an increase in 
the concentration of these amino acids could improve the 
regeneration of the articular cartilage matrix.
As seen in Fig. 5, proline and lysine produce a great 
effect at low concentration, but this effect decreases from 
0.6 mM and 0.85 mM, respectively, while the effect of 
glycine, although lesser at low concentration, exceeds the 
previous ones from ≈ 1.0 mM and, unlike the previous 
ones, this increase continues more persistently even up 
to higher concentrations. The greater effects produced by 
proline and lysine are within their physiological concentra-
tion in plasma, while the effect of glycine corresponds to 
a much higher range, demonstrating a severe generalized 
glycine deficiency for synthesizing collagen. The normal 
plasma concentration of glycine is 0.25-0.5 mM (Felig 
and Wahrent 1971; Javitt et al. 2001), which corresponds 
to a normal intake of 1.50-3.00 g/day (Gibson et al. 2002). 
According to the results reported by Javitt et al. (2001), 
an increase in the diet of 10 g/day could increase the plas-
matic concentration between 3 and 4 times up to 1–2 mM, 
which means an increase about 200% in collagen synthesis 
(Fig. 5b).
An important key to understanding these results is the 
fact that glycine, the most necessary amino acid for colla-
gen synthesis, is highly essential so it must necessarily be 
incorporated into the diet as a nutritional supplement; this 
need is generalized in all animals from ≈ 30 kg of body 
mass and increases with body weight. In a 70-kg human 
being, this glycine deficiency is ≈ 10 g daily—probably 
the highest of the essential amino acids, according to our 
previous results (Meléndez-Hevia et al. 2009); see also 
(Gibson et al. 2002).
Several works have shown that collagen hydrolysate 
could enhance the biosynthesis of type II collagen by 
chondrocytes in vitro and may be a way to treat osteoar-
thritis (Ameye and Chee 2006; Bello and Oesser 2006; 
McAlindon et al. 2011; Moskowitz 2000; Oesser et al. 
1999). Collagen hydrolysate has 33% glycine residues 
(25% of its mass), so 10 g of hydrolysate (the daily dose 
used) means 2.5 g of glycine, which is insufficient for the 
metabolic needs. It may produce a slight improvement, 
but better results could be achieved with a daily dose of 
10 g of glycine which we are proposing here. On the other 
hand, gelatin or collagen hydrolysate are not advantageous 
Fig. 6  Effect of amino acids on chondrocyte growth. Growth curves 
of chondrocytes under amino acid concentrations that provoked 
the highest type II collagen synthesis, according to data shown in 
Fig. 5(a) and (b). Green hexagon: glycine, 6.90 mM (green line); blue 
square: l-proline, 0.60 mM (blue line); red rectangle: l-lysine, 0.85 
mM (red line); gray circle: control (black line)
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as proline or lysine sources because their hydroxylated 
forms, which means about 30-50% of these amino acid 
residues (Barnes et al. 1974), are useless for reutilization. 
Thus, although results with collagen hydrolysate may be 
moderate, they are an indication of the glycine needed to 
propitiate cartilage regeneration.
Therefore, increasing glycine in the diet could be a 
possible way of contributing to fight and prevention of 
osteoarthritis to improve cartilage regeneration by means 
of enhancing collagen synthesis. It may be that the defi-
ciencies mentioned above are not the only cause, but it is 
certainly a feasible place to start. To this end our results 
suggest a viable strategy through increasing the amounts 
of these amino acids (glycine especially) in the diet. As 
these deficiencies will obviously affect other connective or 
mechanical tissues, such as bones, tendons, ligaments and 
skin, we would like to remark that this conclusion might 
also well be applied in the treatment of these damaged 
tissues in conditions such as osteoporosis.
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